Prevention & lipidsCohort study
Use of combination therapy is associated with improved low-density lipoprotein (LDL) cholesterol management: 1-year follow-up results from the European observational SANTORINI study
- Prospective observational cohort study
- multinational (14 European countries)
- 1-year prospective follow-up
Authors' conclusion
Lipid-lowering therapy use and achievement of risk-based lipid goals increased over 1-year follow-up particularly when combination LLT was used.
Study context
- Population
- Patients at high or very high cardiovascular (CV) risk in 14 European countries, recruited March 2020 to February 20217,210 with baseline and follow-up LDL-C
- Participants
- 9,559 patients
- Exposure
- Lipid-lowering therapy (LLT) and LDL-C goal attainment at 1-year follow-up vs baseline
- Outcome
- 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) risk-based LDL-C goal attainment (<1.4 mmol/L very high CV risk; <1.8 mmol/L high CV risk)
- Follow-up
- 1-year follow-up
Main finding
As reported in the abstract
LDL-C goal attainment
Observational data: associations, not effects.
Further findings
LDL-C goal attainment by therapy · 1-year follow-up
LLT use · 1-year follow-up
- LLT escalated
- one-third of patients
- LLT unchanged
- two-thirds
- Monotherapy use, baseline to follow-up
- 53.6 to 57.1%
- Combination therapy use, baseline to follow-up
- 25.6% to 37.9%
Mean LDL-C · 1-year follow-up
- Mean LDL-C decreased from baseline to follow-up
- 2.4 to 2.0 mmol/L
Original publication
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. Published 11 June 2024. doi:10.1093/eurjpc/zwae199
Summarised from the published abstract; every number is checked against it